Immunome (IMNM) Expected to Announce Quarterly Earnings on Wednesday

Immunome (NASDAQ:IMNM) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.51) per share and revenue of $0.1670 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunome Price Performance

Shares of IMNM opened at $23.22 on Wednesday. The company has a 50-day moving average of $21.15 and a two-hundred day moving average of $22.00. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of -9.76 and a beta of 2.07. Immunome has a one year low of $8.66 and a one year high of $27.65.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Leerink Partners reduced their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Finally, Citigroup reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Insiders Place Their Bets

In other Immunome news, Director Isaac Barchas sold 16,906 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $24.20, for a total value of $409,125.20. Following the transaction, the director owned 108,504 shares in the company, valued at approximately $2,625,796.80. This represents a 13.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the completion of the sale, the insider owned 15,805 shares of the company’s stock, valued at approximately $357,509.10. The trade was a 77.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 472,142 shares of company stock valued at $10,262,648 over the last ninety days. Insiders own 7.21% of the company’s stock.

Hedge Funds Weigh In On Immunome

Hedge funds have recently modified their holdings of the stock. Creative Planning raised its holdings in shares of Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Immunome by 14.4% in the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after purchasing an additional 935 shares in the last quarter. California State Teachers Retirement System grew its stake in Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after purchasing an additional 1,167 shares in the last quarter. Virtus Investment Advisers LLC increased its position in Immunome by 16.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock worth $292,000 after purchasing an additional 1,970 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.